Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHORT-HER: 3 vs 12 months of Trastuzumab in HER2+ breast cancer
NCT00629278Phase 3Unknown
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Dec 2007
- Primary completion
- Dec 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab in breast cancer, sponsored by Azienda Ospedaliera Universitaria Policlinico. Status: unknown.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00629278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00629278.